SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
PRINCETON, N.J., Aug. 22, 2017 -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that Al Altomari, Chairman and CEO will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12, 2017 at 9:10 AM ET in New York.
To access the live and archived webcasts of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. The webcast will be archived on Agile Therapeutics website for 60 days following the event.
About Agile Therapeutics
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. Follow Agile on social media: @agilether. The company may occasionally disseminate material, nonpublic information on the company website.
About Twirla®
Twirla (ethinyl estradiol and levonorgestrel transdermal system) or AG200-15 is an investigational once-weekly prescription contraceptive patch. AG200-15 is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE), a synthetic estrogen, and levonorgestrel (LNG), a type of progestin, a synthetic steroid hormone. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.
Contact: Mary Coleman - 609-683-1880
